Phase II trial of amrubicin treatment as palliative-intended chemotherapy for previously treated malignant pleural mesothelioma
Phase of Trial: Phase II
Latest Information Update: 25 May 2018
At a glance
- Drugs Amrubicin (Primary)
- Indications Mesothelioma
- Focus Therapeutic Use
- 20 May 2018 Planned End Date changed from 31 May 2018 to 31 May 2020.
- 28 Jun 2013 Planned end date (31 May 2018) added as reported by University Hospital Medical Information Network - Japan.
- 01 Jun 2013 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.